Market closedNon-fractional
Stoke Therapeutics/STOK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Stoke Therapeutics
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
Ticker
STOK
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Bedford, United States
Employees
110
Website
www.stoketherapeutics.com
STOK Metrics
BasicAdvanced
$759M
Market cap
-
P/E ratio
-$2.42
EPS
0.81
Beta
-
Dividend rate
Price and volume
Market cap
$759M
Beta
0.81
Financial strength
Current ratio
5.431
Quick ratio
5.018
Long term debt to equity
2.939
Total debt to equity
4.516
Management effectiveness
Return on assets (TTM)
-30.41%
Return on equity (TTM)
-61.29%
Valuation
Price to revenue (TTM)
83.385
Price to book
4.84
Price to tangible book (TTM)
4.84
Price to free cash flow (TTM)
-7.629
Growth
Revenue change (TTM)
-46.12%
Earnings per share change (TTM)
-1.94%
3-year earnings per share growth (CAGR)
12.77%
What the Analysts think about STOK
Analyst Ratings
Majority rating from 9 analysts.
STOK Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$4.2M
50.00%
Net income
-$26M
-2.23%
Profit margin
-626.19%
-34.82%
STOK Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.69
-$0.55
-$0.60
-$0.57
-
Expected
-$0.64
-$0.63
-$0.63
-$0.61
-$0.55
Surprise
8.43%
-12.41%
-4.76%
-6.56%
-
STOK News
AllArticlesVideos
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire·1 month ago
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Seeking Alpha·1 month ago
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Stoke Therapeutics stock?
Stoke Therapeutics (STOK) has a market cap of $759M as of July 27, 2024.
What is the P/E ratio for Stoke Therapeutics stock?
The price to earnings (P/E) ratio for Stoke Therapeutics (STOK) stock is 0 as of July 27, 2024.
Does Stoke Therapeutics stock pay dividends?
No, Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Stoke Therapeutics dividend payment date?
Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders.
What is the beta indicator for Stoke Therapeutics?
Stoke Therapeutics (STOK) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Stoke Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.